Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan.

Trial Profile

Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 19 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jul 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as per ClinicalTrials.gov record.
    • 23 May 2015 Planned number of patients changed from 20 to 6 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top